全文获取类型
收费全文 | 1298篇 |
免费 | 72篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 57篇 |
妇产科学 | 18篇 |
基础医学 | 137篇 |
口腔科学 | 37篇 |
临床医学 | 173篇 |
内科学 | 236篇 |
皮肤病学 | 5篇 |
神经病学 | 59篇 |
特种医学 | 206篇 |
外科学 | 101篇 |
综合类 | 22篇 |
预防医学 | 138篇 |
眼科学 | 14篇 |
药学 | 96篇 |
中国医学 | 1篇 |
肿瘤学 | 89篇 |
出版年
2021年 | 13篇 |
2020年 | 7篇 |
2019年 | 6篇 |
2018年 | 6篇 |
2017年 | 10篇 |
2016年 | 12篇 |
2015年 | 9篇 |
2014年 | 8篇 |
2013年 | 33篇 |
2012年 | 54篇 |
2011年 | 65篇 |
2010年 | 36篇 |
2009年 | 30篇 |
2008年 | 45篇 |
2007年 | 85篇 |
2006年 | 41篇 |
2005年 | 48篇 |
2004年 | 37篇 |
2003年 | 48篇 |
2002年 | 31篇 |
2001年 | 41篇 |
2000年 | 45篇 |
1999年 | 42篇 |
1998年 | 40篇 |
1997年 | 50篇 |
1996年 | 29篇 |
1995年 | 30篇 |
1994年 | 23篇 |
1993年 | 18篇 |
1992年 | 31篇 |
1991年 | 36篇 |
1990年 | 23篇 |
1989年 | 39篇 |
1988年 | 40篇 |
1987年 | 37篇 |
1986年 | 32篇 |
1985年 | 36篇 |
1984年 | 21篇 |
1983年 | 11篇 |
1982年 | 21篇 |
1981年 | 11篇 |
1980年 | 17篇 |
1979年 | 13篇 |
1978年 | 10篇 |
1977年 | 14篇 |
1976年 | 19篇 |
1975年 | 10篇 |
1973年 | 5篇 |
1971年 | 4篇 |
1967年 | 3篇 |
排序方式: 共有1392条查询结果,搜索用时 15 毫秒
1.
R T Means N J Olsen S B Krantz E N Dessypris S E Graber W J Stone V L O'Neil T Pincus 《Arthritis and rheumatism》1989,32(5):638-642
Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis. 相似文献
2.
A patient with malignant peritoneal mesothelioma and a diffuse pulmonary infiltrate is described. Computed tomographic scanning suggested lymphangitis carcinomatosa. This was confirmed on transbronchial biopsy to be due to metastatic mesothelioma. 相似文献
3.
4.
Golli M; Van Nhieu JT; Mathieu D; Zafrani ES; Cherqui D; Dhumeaux D; Vasile N; Rahmouni A 《Radiology》1994,190(3):741
5.
6.
R Malcolm J M Von P M O'Neil H S Currey J D Sexauer E Riddle 《Southern medical journal》1988,81(5):632-639
This article updates a paper published in this journal more than a decade ago. We detail the ensuing decade's developments in the treatment of obesity, reviewing innovations, established techniques, and the current status of behavior modification. We evaluate newer developments, such as anorectic drugs, very low calorie diets, and intragastric balloon bezoars, and we describe other approaches to the treatment of obesity, such as residential and comprehensive outpatient programs. We conclude by recommending a multidisciplinary approach to this complex problem. 相似文献
7.
8.
MGC Hendriks P Dogterom JT Ebels B Oosterhuis LR Geertsema T Hulot G Bianchetti and JHG Jonkman 《Fundamental & clinical pharmacology》1998,12(5):559-565
Summary— In the present study we have compared the steady state biopharmaceutic characteristics of four diltiazem once daily controlled release capsules: Mono-Tildiem LP 300® (300 mg), Adizem® XL (300 mg)1, Cardizem® (300 mg) and Dilacor® (240 mg). Sixteen healthy male volunteers (aged 22.9 ± 3.3 years, range 19–31 years) completed an open label, multiple oral dose, randomized, four-period crossover study without a washout period in between. The volunteers received each diltiazem formulation once daily for four days. Trough diltiazem and metabolites plasma concentrations were determined on days 3 and 4. The 24-h plasma concentration-time profiles were assessed after the dose on day 4 of each period. The following steady state pharmacokinetic parameters for diltiazem were calculated: the minimum plasma concentration (cmin), the maximum plasma concentration (cmax), the time to reach that concentration (tmax), the time interval during which the plasma concentration exceeds 50% of cmax (t50), the area under the plasma concentration-time curve (AUC72–96) and the peak-to-trough fluctuation (PTF). For the metabolites of diltiazem, N-mono-desmethyl-diltiazem (NDM) and desacetyldiltiazem (DAD), AUC72–96 (AUCNDM and AUCDAD) and the ratio metabolite/parent compound were calculated. Steady state was achieved on day 3. Except one, all controlled release formulations have satisfactory controlled release properties allowing once daily administration. However, significant (P < 0.05) differences were found between the pharmacokinetic characteristics which do not allow exchange of the various formulations. Concentrations well below 50 ng·mL-1 in the morning hours were observed for Dilacor® (240 mg) and Adizem® XL (300 mg), which could be a disadvantage of these formulations as it is well-known that ischaemic events occur at a higher rate during that part of the day. The plasma concentration profiles of NDM and DAD, the major circulating metabolites, parallel the plasma concentration profiles for the parent compound. From a clinical point of view, all treatments were well tolerated. 相似文献
9.
Aldosterone regulation of sodium and potassium transport in the cortical collecting duct 总被引:1,自引:0,他引:1
R G O'Neil 《Seminars in Nephrology》1990,10(4):365-374